Our drug discovery platform allows us to create drug candidates for diverse disease indications. Our internal development is focused on advancing candidates for the treatment of autoimmune and inflammatory diseases.
In our pipeline, we have clinical stage programs in cancer and respiratory diseases, and other early stage programs. We seek to advance these programs through collaborative alliances with pharmaceuticals and biotechnology companies. Collaborations are an important part of our business as they provide the necessary resources and drug development experience to advance our compounds in the collaborator’s programs.